News
-
-
-
COMMUNIQUÉ DE PRESSE
Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05
Tanvex BioPharma USA, Inc. receives FDA approval for NYPOZI™ biosimilar and FDA BLA acceptance for TX-05, showcasing expertise in biologics development and manufacturing -
COMMUNIQUÉ DE PRESSE
Tanvex CDMO Launch Empowers Advancements in Novel Biologics and Biosimilars